Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
13hon MSN
Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...
A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback